文章摘要
宫颈癌化疗近期疗效差异与DNA聚合酶ζ亚基REV3基因多态性的关系
Relationship between difference in short-term curative effect of chemotherapy for cervical cancer and DNA polymerase ζ subunit REV3 gene polymorphism
投稿时间：2020-10-27  
DOI：10.3969/j.issn.1000-0399.2021.09.005
中文关键词: 宫颈癌  DNA聚合酶ζ  REV3基因  多态性  化疗
英文关键词: Cervical cancer  DNA polymerase ζ  REV3 gene  Polymorphism  Chemotherapy
基金项目:河南省重点研发与推广专项（项目编号：2020-414），漯河医学高等专科学校创新创业发展能力提升工程项目（项目编号：2019-LYZKYZD017）
作者单位
杨然 473009 河南省南阳市中心医院妇产科 
张清伟 462002 河南漯河 漯河医学高等专科学校第一附属医院妇科 
冯磊 473009 河南省南阳市中心医院妇产科 
董莉丽 473009 河南省南阳市中心医院妇产科 
李松 473009 河南省南阳市中心医院妇产科 
摘要点击次数: 1009
全文下载次数: 0
中文摘要:
      目的 探究宫颈癌近期化疗效果差异与DNA聚合酶ζ（Polζ）亚基REV3基因多态性的关系。方法 选取2018年1月至2019年12月河南省南阳市中心医院收治的96例宫颈癌患者（宫颈癌组），治疗前均采血提取基因组DNA，检测Polζ亚基REV3基因（rs181294、rs240966、rs465646）多态性，与同期收治的50例同龄正常体检者进行对照，分析遗传平衡情况；所有宫颈癌患者均给予铂类化疗，4个周期后评估化疗疗效，按治疗效果分为敏感组与非敏感组，分析近期疗效与REV3基因多态性的关系。结果 宫颈癌组REV3 rs181294位点G/A型、A/A型及A等位基因频率高于对照组，rs465646位点A/G、G/G基因型及G等位基因频率高于对照组，差异均有统计学意义（P<0.05）。携带REV3 rs181294位点A/A基因型宫颈癌易感风险高于携带G/G型（P<0.05）；携带rs465646位点A/G、G/G基因型宫颈癌易感风险高于携带A/A型（P<0.05）；携带REV3 rs181294位点A型等位基因宫颈癌易感风险高于携带G等位基因（P<0.05）；携带rs465646位点G等位基因宫颈癌易感风险高于携带A等位基因（P<0.05），差异均有统计学意义。96例宫颈癌患者完全缓解8例（8.33%），部分缓解41例（42.71%），稳定40例（41.67%），进展7例（7.29%）。敏感组REV3 rs181294位点G/A型、A/A型及A等位基因频率高于非敏感组，rs465646位点A/G、G/G基因型及G等位基因频率低于非敏感组，差异有统计学意义（P<0.05）。结论 携带Polζ亚基REV3 rs181294位点G/A型、A/A型及A等位基因及rs465646位点A/G、G/G基因型及等位基因G均可能增加宫颈癌易感性及铂类化疗不敏感风险。
英文摘要:
      Objective To explore the relationship between the difference in short-term curative effect of chemotherapy for cervical cancer and DNA polymerase ζ (Polζ) subunit REV3 gene polymorphism. Methods Ninety-six patients with cervical cancer (cervical cancer group) admitted to Nanyang Central Hospital, Henan Province, were selected between January 2018 and December 2019. Blood samples were collected before treatment to extract genomic DNA, and polymorphism of Polζ subunit REV3 gene (rs181294, rs240966, rs465646) was detected. Meanwhile, 50 subjects at the same age were selected as control, and genetic balance was analyzed. All cervical cancer patients were treated with platinum-based chemotherapy, and the curative effect of chemotherapy was evaluated four cycles later. The patients were divided into sensitive group and non-sensitive group according to the effect. The relationship between the short-term curative effect and REV3 gene polymorphisms was analyzed. Results The frequencies of genotype G/A, genotype A/A and A allele at REV3 rs181294, frequencies of genotype A/G, genotype G/G and G allele at rs465646 in the cervical cancer group were higher than those in the control group, and the differences were statistically significant (P<0.05). Patients carrying A/A genotype at REV3 rs181294, A/G genotype and G/G genotype at rs465646, type A allele at REV3 rs181294 and G allele at rs465646 had a higher risk of cervical cancer than those carrying G/G genotype at REV3 rs181294, A/A genotype at rs465646, G allele at REV3 rs181294 and A allele at rs465646 (P<0.05). Among the 96 patients with cervical cancer, there were 8 cases with complete remission (8.33%), 41 cases with partial remission (42.71%) and 40 cases in stable condition (41.67%). Genotype G/A, genotype A/A and A allele frequencies of REV3 rs181294, genotype A/G, genotype G/G and G allele frequencies of rs465646 in the sensitive group were higher than those in non-sensitive group, and the differences were statistically significant (P<0.05). Conclusions Carrying genotype G/A, genotype A/A and A allele of rs181294, genotype A/G, genotype G/G and G allele of rs465646 on Polζ subunit REV3 may increase the susceptibility to cervical cancer and the risk of platinum-based chemotherapy insensitivity.
查看全文   查看/发表评论  下载PDF阅读器
关闭